-
ASCO Voices from China | Huafeng Wang: Advancing Innovation and Expanding Possibilities—A Novel BCL-2 Inhibitor Brings New Hope for AML and MDS
Despite significant advances in recent years, the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) continues to present major clinical challenges. Existing therapies offer limited efficacy for many patients, particularly those with high-risk disease, highlighting a substantial unmet medical need.
-
ASCO Voices from China | Zhihui Li: Large Real-World Study Highlights the Value of CAR-T-to-Transplant Consolidation in R/R B-ALL
The treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) remains a major clinical challenge. While CAR-T cell therapy can induce rapid and deep remissions, many patients continue to face a substantial risk of relapse. Consolidation with allogeneic hematopoietic stem cell transplantation (allo-HSCT) following CAR-T therapy has emerged as a promising curative strategy. However, evidence…
-
ASCO China Voice | From Post–CAR-T Relapse to Treatment Redesign: Director Yajing Zhang’s Team Reports Exploratory Results of Sequential Multi-Antigen CAR-T Therapy in B-Cell Lymphoma
The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting is currently underway in Chicago, bringing together oncology experts from around the world to showcase the latest advances in cancer research and treatment.
-
ASCO China Voice | From Post–CAR-T Relapse to Treatment Redesign: Director Yajing Zhang’s Team Reports Exploratory Results of Sequential Multi-Antigen CAR-T Therapy in B-Cell Lymphoma
The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting is currently underway in Chicago, bringing together oncology experts from around the world to showcase the latest advances in cancer research and treatment.
-
CGOG 2026 Day 2 | ASCO Neuroendocrine Tumors Highlights Session
The 2026 Peking University Gastrointestinal Oncology Forum and the 16th CGOG Annual Meeting were held in Beijing from June 9–13, 2026. On June 10, the dedicated ASCO Neuroendocrine Tumors Highlights Session brought together leading Chinese experts to provide in-depth reviews of the latest advances in neuroendocrine tumor (NET) research presented at the 2026 ASCO Annual…
-
CGOG 2026 Day 3 | ASCO Precision Oncology and Novel Therapeutics Highlights Session
On June 11, the online program of the 16th Peking University Gastrointestinal Oncology Forum and CGOG Annual Meeting continued with a dedicated session, “ASCO Highlights: Precision Oncology and Novel Therapeutics.” The session was livestreamed across multiple platforms and attracted more than 15,000 online viewers.
-
CGOG 2026 Day 3 | ASCO Highlights Session on Colorectal Cancer
On June 11, Day 3 of the 16th Peking University Gastrointestinal Oncology Forum and CGOG Annual Meeting featured the 2026 ASCO Highlights Session on Colorectal Cancer, where leading experts provided in-depth reviews and discussions of the latest advances presented at the 2026 ASCO Annual Meeting. The session was livestreamed across multiple platforms and attracted more…
-
Exclusive Interview with Prof. Weiren Huang: Reflecting on the Discipline’s Legacy and the Next Decade of Tumor Organoids | The 2nd Peking University Urology Forum
During the 2nd Peking University Urology Forum and the celebration of the 80th anniversary of the Department of Urology at Peking University First Hospital, Oncology Frontier – UroStream interviewed Prof. Weiren Huang from the Department of Urology, First Affiliated Hospital of Shenzhen University (Shenzhen Second People’s Hospital).
Connecting Medical Expertise through Media